Development of destructive thyroiditis and diabetes mellitus after three injections of pembrolizumab for skin melanoma

The exponential rise in the use of immune checkpoint inhibitors (Ipilimumab, Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab, and Avelumab) as the new standard for cancer treatment increase the incidence the immune-related adverse events due to immune activation. Endocrine immune-related adverse...

Descripción completa

Detalles Bibliográficos
Autores principales: Glibka, A. A., Mel`nichenko, G. A., Mikhina, M. S., Mazurina, N. V., Kharkevich, G. Yu.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrinology Research Centre 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926137/
https://www.ncbi.nlm.nih.gov/pubmed/34004100
http://dx.doi.org/10.14341/probl12698

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926137/
https://www.ncbi.nlm.nih.gov/pubmed/34004100
http://dx.doi.org/10.14341/probl12698

Ejemplares similares